US curb on J&J vaccine threatens African manufacturing plans
FDA says risks of J&J shot outweighs benefits for adults who could get an alternative
The recent decision by US authorities to limit the use of Johnson & Johnson’s (J&J) coronavirus vaccine over concerns about a rare blood-clotting disorder will fuel hesitancy about its use in other parts of the world and may jeopardise SA’s vaccine manufacturing ambitions, Medical Research Council president Glenda Gray warned on Monday.
The US Food and Drug Administration (FDA) announced on Friday that people should get immunised with mRNA vaccines made by Pfizer or Moderna instead of J&J’s shot, unless they had medical reasons not to, did not want an mRNA jab, or mRNA shots were not available. Citing data previously flagged by other US authorities, the FDA said the risks of the J&J shot outweighed the benefits for adults who could get an alternative...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.